United Therapeutics has scored a regulatory green light to start clinical trials for its genetically modified pig kidneys to ...

UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics ...

Kingswood Wealth Advisors LLC bought a new position in shares of United Therapeutics Co. (NASDAQ:UTHR – Free Report) during ...

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions, according to a recent SEC filing. On February 3, Benkowitz sold shares ...

NEW YORK, NY / ACCESS Newswire / February 5, 2025 / If you suffered a loss on your Applied Therapeutics, Inc. (NASDAQ:APLT) investment and want ...

Several other equities research analysts have also commented on the stock. UBS Group increased their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the company a ...

We recently compiled a list of the 10 Best Rebound Stocks To Invest In Now. In this article, we are going to take a look at ...

Silver Spring, MD-based United Therapeutics Corporation markets four ... UTHR is a Zacks Rank #2 (Buy) stock, with a Growth Style Score of B and VGM Score of A. Earnings are expected to grow ...

Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for ...

United Therapeutics' clinical trial represents a ... potentially influencing stock movements in the sector. ANAB is expected to release Phase II rheumatoid arthritis data for Rosnilimab, while ...

Each stock is assigned a rating of A ... Silver Spring, MD-based United Therapeutics Corporation markets four medicines in the United States to treat pulmonary arterial hypertension (PAH ...